- Policy
- Celltrion abandoned clinical trials of CT-P59
- by Lee, Jeong-Hwan Mar 2, 2021 06:25am
- It was found that Celltrion gave up the clinical trial of CT-P59, a prophylactic antibody treatment to respond to COVID-19. Celltrion decided to suspend the project selection agreement in less than a month after it was selected for the government support project in December of last year. Celltrion cited the difficulty of developing vaccine
- Policy
- KDCA on cost-effectiveness of expanding HPV vaccination
- by Lee, Tak-Sun Mar 2, 2021 06:25am
- The government is apparently conducting a study on the cost-effectiveness of expanding the human papillomavirus (HPV) vaccination subject and vaccine types. The outcome of the research could affect the pharmaceutical industry. On Feb. 24, the Korea Disease Control and Prevention Agency (KDCA) official answered Democratic Party Lawmaker C
- Policy
- The MFDS released the minutes of the Advisory Meeting
- by Lee, Tak-Sun Mar 2, 2021 06:25am
- The Central Pharmaceutical Affairs Review Committee, a legal advisory body of the MFDS, also found that there was a controversy over the AstraZeneca (AZ) COVID-19 vaccine, which has been delayed for vaccination for 65-year-olds. It is administered to adults over the age of 18, including those over 65, but there was an opinion that the eld
- Company
- Xospata can be prescribed at general hospitals
- by Eo, Yun-Ho Feb 26, 2021 06:26am
- Acute myeloid leukemia treatment Xospata can be prescribed at general hospitals. According to related industries, Xospata (Gilteritinib), a drug for acute myeloid leukemia (AML) of Astellas Korea, has passed the drug committee (DC) of SNUH and SMC, and is also in progress at other major hospitals nationwide. This drug has already been pre
- Company
- Prolia's sales amounted to ₩75.1 billion in 4 years
- by Kim, Jin-Gu Feb 26, 2021 06:26am
- Amgen's Prolia (Denosumab) ranked first in the osteoporosis treatment market. Amgen's Evenity (Romosozumab) is expected to start earning sales this year. Amgen, which has established a lineup leading to Evenity-Prolia in the osteoporosis treatment market, is expected to sustain high sales for some time. Most of the bisphosphonates, which had
- Company
- “Amgen sotorasib as personalized lung cancer treatment”
- by Feb 26, 2021 06:26am
- A Kirsten rat sarcoma virus (KRAS) targeted therapy for treating lung cancer patients is finally getting close to an arm’s reach after 40 years. A KRAS inhibitor sotorasib (codename: AMG 510) in development by Amgen has been authorized by the U.S. Food and Drug Administration (FDA) for a priority review on Feb. 17. A first KRAS treatment co
- Company
- Cancer Committee passes Korean-made new drug Leclaza
- by Eo, Yun-Ho Feb 25, 2021 06:24am
- A Korean-made new drug Leclaza passed the first threshold to receive the National Health Insurance (NHI) listing. A pharmaceutical industry source reported the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee has approved of the NHI reimbursement on Yuhan Corporation’s Leclaza (lazertinib), a third-gen
- Policy
- The MFDS is pre-reviewing a combination of Mifegyne
- by Lee, Jeong-Hwan Feb 25, 2021 06:23am
- The MFDS announced that it is in the process of applying for a preliminary review of the combination drug Mifepristone(generic for Mifegyne) and Misoprostol. The MFDS has also initiated a guideline for safe use of abortion pill and is also planning to collect opinions from experts such as gynecologists and women's groups. On the 24th,
- Policy
- Can Pfizer Vaccine be vaccinated immediately after arrival?
- by Lee, Tak-Sun Feb 24, 2021 06:03am
- 117,000 doses of Pfizer's COVID-19 vaccine supplied by the COVAX Facility will arrive in Korea on the 26th, and attention is focused on whether vaccination is possible immediately. COVAX Facility's Pfizer vaccine is highly likely to greatly simplify the assay method, as it is introduced in Korea through a special import rather than a domesti
- Company
- Pfizer's Benefix was approved as a prophylactic treatment
- by Feb 24, 2021 06:02am
- Pfizer Korea (CEO Dong-wook Oh) &8203;&8203;announced on the 22nd that Benefix (Recombinant Blood Coagulation Factor Ⅸ), a hemophilia B treatment, was additionally approved by the MFDS for an indication for routine preventive therapy administered once a week. For those over 12 years of age who are injecting Benefix, a dose of 100 IU/kg
